| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 30.14▼ | 30.84▼ | 31.28▼ | 38.28▼ | 43.72▼ |
| MA10 | 30.43▼ | 32.21▼ | 32.49▼ | 43.90▼ | 44.17▼ |
| MA20 | 30.95▼ | 32.63▼ | 35.65▼ | 45.70▼ | 41.67▼ |
| MA50 | 32.24▼ | 39.04▼ | 43.44▼ | 45.47▼ | 26.88▲ |
| MA100 | 32.75▼ | 44.18▼ | 46.49▼ | 41.61▼ | N/A |
| MA200 | 35.17▼ | 46.42▼ | 46.00▼ | 30.35▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.041▼ | 0.070▲ | -0.073▼ | -2.322▼ | -1.435▼ |
| RSI | 23.519▼ | 24.765▼ | 25.840▼ | 24.461▼ | 40.748▼ |
| STOCH | 7.516▼ | 1.731▼ | 34.653 | 19.945▼ | 55.861 |
| WILL %R | -95.906▼ | -98.664▼ | -98.664▼ | -99.288▼ | -99.288▼ |
| CCI | -123.386▼ | -136.890▼ | -150.884▼ | -176.899▼ | -167.832▼ |
|
Wednesday, March 25, 2026 01:28 PM
Maze Therapeutics (NASDAQ:MAZE) outlined positive Phase II results from its open-label HORIZON study evaluating MZE829 in patients with APOL1-mediated kidney disease (AMKD), highlighting reductions in ...
|
|
Wednesday, March 25, 2026 01:06 PM
This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider sale.
|
|
Wednesday, March 25, 2026 08:38 AM
Maze Therapeutics (MAZE) stock plunged even as the company posts positive Phase 2 trial data for lead asset MZE829 in APOL1-mediated kidney disease. Read more here.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 27/03/26 | 30.84 | 31.60 | 29.86 | 29.94 | 321,296 |
| 26/03/26 | 31.11 | 35.2798 | 30.16 | 31.71 | 1,716,898 |
| 25/03/26 | 40.00 | 41.00 | 29.77 | 31.73 | 7,832,474 |
| 24/03/26 | 48.16 | 49.25 | 46.06 | 49.00 | 550,253 |
| 23/03/26 | 48.87 | 49.18 | 47.00 | 49.00 | 512,668 |
| 20/03/26 | 49.31 | 50.63 | 47.76 | 48.03 | 1,104,390 |
| 19/03/26 | 47.47 | 50.00 | 46.67 | 49.43 | 648,212 |
| 18/03/26 | 50.42 | 51.74 | 48.005 | 48.47 | 491,484 |
| 17/03/26 | 51.02 | 53.00 | 49.98 | 50.39 | 922,200 |
| 16/03/26 | 50.96 | 53.65 | 50.60 | 51.26 | 899,708 |
|
|
||||
|
|
||||
|
|